Therapeutic potential of targeting LAG-3 in cancer
Immune checkpoint inhibitors targeting negative regulatory checkpoints including programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 have produced significant improvements in progression-free survival (PFS) and overall survival in multiple solid tumors. Lymphocyte activation ge...
Saved in:
| Main Authors: | Diwakar Davar, Ana Carrizosa Anderson, Ivan Diaz-Padilla |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/7/e011652.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer
by: Xiangyu Qiu, et al.
Published: (2024-11-01) -
LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy
by: Camil Ciprian Mireștean, et al.
Published: (2025-04-01) -
Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging
by: Zhen Quan, et al.
Published: (2025-08-01) -
Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
by: Chenyu Lu, et al.
Published: (2024-03-01) -
Disgust-induced attentional blink at Lag3: a diagnostic and therapeutic approach to depression
by: Yingying Wang, et al.
Published: (2025-04-01)